| Project/Area Number |
23659286
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
ARIMA Naomichi 鹿児島大学, 大学院・医歯学総合研究科, 教授 (30175997)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITO Yuji 鹿児島大学, 大学院・理工学研究科, 教授 (60223195)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 抗体療法 / TCR-Vβ / T細胞性リンパ腫 / 治療薬 / Ｔ細胞性腫瘍 / 成人Ｔ細胞白血病 / ファージデイスプレイ法 / scFv antibody / 分子標的療法 / 患者TCRに対する抗体療法 |
|---|
| Research Abstract |
Under admission of IRB, repertoire of TCRVb of leukemic cells derived from an ATL patient was demonstrated Vb2. Full length of TCR αand βwere separated from extracted RNA by 5’RACE method. TCRb expressing vector was established using lenti-virus bector system, and infected into Jurkat cells which expresses successfully trnsfected TCRβ2 protein. On the other hands, human anbibody heavy and light chain expressing phage library was constructed using normal health lymphocyte RNA. Using these two materials, we further study establishment of malignant T cell targeted antibody therapy.
|
